Cutaneous squamous cell carcinoma : Incidence, risk factors, diagnosis, and staging - 13/01/18
Abstract |
Cutaneous squamous cell carcinoma (cSCC), a malignant proliferation of cutaneous epithelium, represents 20% to 50% of skin cancers. Although the majority of cSCCs are successfully eradicated by surgical excision, a subset of cSCC possesses features associated with a higher likelihood of recurrence, metastasis, and death. The proper identification of these aggressive cSCCs can guide additional work-up and management. In the first article in this continuing medical education series, we discuss the incidence, recurrence rates, mortality rates, and risk factors associated with cSCC and review the staging systems used to stratify patients into high- and low-risk groups. The second article in this series reviews the treatment options for cSCC, with focused attention on the management of high-stage tumors.
Le texte complet de cet article est disponible en PDF.Key words : 5-fluorouracil, imiquimod, ingenol mebutate, acitretin, American Joint Commission on Cancer, Brigham and Women's Hospital staging system, capecitabine, CDKN2A, cetuximab, chemotherapy, classification, cSCC, CT, cutaneous squamous cell carcinoma, familial cancer syndromes, high-risk, management, MRI, N1S3 staging, nicotinamide, nivolumab, NOTCH1, p53, PD-1, pembrolizumab, photodynamic therapy, radiation therapy, Ras, retinoids, risk factors, sentinel lymph node biopsy, sirolimus, staging
Abbreviations used : AJCC-8, BCC, BWH, CDKN2A, cSCC, EGFR, HPV, MAPK, N1S3, PD1, SOTR, TP53
Plan
Funding sources: None. |
|
Dr Schmults was involved in the development of the Brigham and Women's tumor staging system for cutaneous squamous cell carcinoma. Drs Que and Zwald have no conflicts of interest to declare. |
|
Reprints not available from the authors. |
|
Date of release: February 2018 |
|
Expiration date: February 2021 |
Vol 78 - N° 2
P. 237-247 - février 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?